This study is testing a drug called zelquistinel to see if it can help reduce symptoms of major depressive disorder (MDD) in adults. Researchers also want to understand its safety. You might be able to join if you are between 18 and 64 years old and have been diagnosed with MDD. The main goal is to see if zelquistinel lowers depression scores more than a placebo (a pill with no medicine). Participants will take either zelquistinel or a placebo once a week for 6 weeks. Your depression symptoms will be checked weekly during this time.

Study design

This is a Phase 2 study that will involve about 164 participants. It is randomized and double-blind, meaning you won't know if you're getting zelquistinel or a placebo, and neither will your study doctor.

What's involved

You will participate in the study for up to 98 days, including screening, 6 weeks of treatment, and a 4-week follow-up. You will visit the clinic once a week during the 6-week treatment period to have your depression assessed.

Compensation

Not stated in the trial record.

Follow-up

After the 6 weeks of treatment, there will be a 4-week follow-up period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.